Blue Flower



The documentations contained in this archive section are provided for historical purposes only. The information contained in each documentation is accurate only as of the date each documentation was originally issued. NOXXON disavows any obligation to update the information contained in such documentations after the date of their issuance.

2019, February 18 - Letter to Shareholders (German: Brief an die Aktionäre)

Presentations
2020, September - Corporate Presentation
2020, September - ESMO Congress 2020 Poster Presentation
  -download poster
  -view presentation
2019, September 30 - Webcast: ESMO Congress 2019 Poster Presentation
  -download poster
  -download presentation
  -view webinar recording
2019, September 23 - Webinar: What’s next in treatment of brain cancer patients? Testing NOX-A12 with Radiotherapy in a Phase 1/2 Clinical Trial
  -download presentation
  -download draft script
  -view webinar recording
2018, September - KOL Event GBM Presentation
2018, September - EquityForum Fall Conference / Herbstkonferenz Presentation
2018, May - ASCO Presentation
2018, May - Bio€quity Presentation

Managers Transactions (as disclosed by company to competent authority)
2020, June 30 - Transactions related to grant of stock options to Aram MangasarianOscar Izeboud
2020, April - Sale of shares effective 17 April 2020, Donald deBethizy
2019, October 09 - Transactions related to grant of stock options to Aram Mangasarian, Donald deBethizy
2019, August -Transaction related to Aug 2019 private placement, share purchases effective 15 Aug 2019: Aram Mangasarian
2019, July -Transactions related to July 2019 rights issue, share purchases effective 23 July 2019: Donald deBethizy (second)
2019, July -Transactions related to July 2019 rights issue, share purchases effective 23 July 2019: Aram Mangasarian
2019, July -Transactions related to July 2019 rights issue, share purchases effective 23 July 2019: Donald deBethizy (first)

2017, July 11 - NOXXON Pharma NV Prospectus approved 10 July 2017 (English with summary of prospectus in French)

Overview and Characteristics of the Convertible Bonds of the financing agreement published on April 23, 2020
as amended on October 14, 2020
2020, October 20 - Overview of the Convertible Bonds 
2020, October 14 - Characteristics of the Convertible Bonds as amended 
2020, October 14 - Press release
2020, April 23 - Characteristics of the Convertible Bonds 
2020, April 23 - Press release

Terms of the Warrants of the financing agreement signed on November 15, 2018
2020, April 17 - Overview of the Warrants
2018, November 16 - Terms of the Warrants
2018, November 16 - Press release

Overview and Characteristics of the Convertible Notes listed on Euronext Access Paris in Sept 2018
2018, December 11 - Overview of the Outstanding Notes Listed on Euronext Access Paris - NOXXON7%PT
2018, November 16 - Issuer conversion notices submitted on November 16, 2018
2018, September - Terms and Conditions
2018, September - Euronext Listing Announcement
2018, November 16 - Press release
2018, September 19 - Press release

Overview and Characteristics of the Notes and Warrants of the financing agreement signed on May 01, 2017
2020, July 21 - Updated Summary Table of ODIRNANE & BSA
2017, May 02 - Characteristics of the Warrants
2017, May 02 - Characteristics of the Notes

2020, April 22 - 2019 Annual Report (Corrected version: contains corrected date of  signature of the audit opinion, and no other changes.)
2020, April 22 - 2019 Annual Report
2019, April 12 - 2018 Annual Report
2018, April 30 - 2017 Annual Report
2017, June 07 - 2016 Annual Report - statutory
2017, April 30 - 2016 Annual Report - non statutory

2016, December 07 - 2015 NOXXON Pharma N.V. IFRS

2019, Half-Year Financial Report as of 30 June 2019
2018, Half-Year Financial Report as of 30 June 2018
2017, Half-Year Financial Report as of 30 June 2017
2017, October 30 - Condensed consolidated interim financial statements as of 30 June 2017
2016, October 31 - Condensed consolidated interim financial statements as of 30 June 2016

2016, September 28 - Information Document